Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Atar

Showing results (341-350 of 405) with videos related to

Pageof 41
Sort By:
European Heart Journal. Cardiovascular Pharmacotherapy|December 28, 2020
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trialRaffaele De Caterina, Giuseppe Patti, Johan Westerbergh, et al.
Circulation|August 29, 2022
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular DiseaseMichelle L O'Donoghue, Robert P Giugliano, Stephen D Wiviott, et al.
Annals of Medicine|April 5, 2021
Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registryMarita Knudsen Pope, Dan Atar, Arne Svilaas, et al.
JACC. Cardiovascular Imaging|January 16, 2022
Cost-Minimization Analysis for Cardiac Revascularization in 12 Health Care Systems Based on the EuroCMR/SPINS RegistriesKarine Moschetti, Raymond Y Kwong, Steffen E Petersen, et al.
The American Journal of Medicine|July 16, 2019
Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AFFreek W A Verheugt, Giuseppe Ambrosio, Dan Atar, et al.
European Journal of Heart Failure|March 3, 2022
Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fractionClara Saldarriaga, Dan Atar, Amanda Stebbins, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 24, 2019
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on StrokePatrick Sulzgruber, Sven Wassmann, Anne Grete Semb, et al.
JACC. Cardiovascular Imaging|September 13, 2014
Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patientsMatthijs van Kranenburg, Michael Magro, Holger Thiele, et al.
European Heart Journal|September 22, 2019
Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1Patrick Sulzgruber, Sven Wassmann, Anne Grete Semb, et al.
European Heart Journal|October 23, 2013
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trialJohn H Alexander, Renato D Lopes, Laine Thomas, et al.
Pageof 41

Showing results (341-350 of 405) with videos related to

Sort By:
Pageof 41
European Heart Journal. Cardiovascular Pharmacotherapy|December 28, 2020
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trialRaffaele De Caterina, Giuseppe Patti, Johan Westerbergh, et al.
Circulation|August 29, 2022
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular DiseaseMichelle L O'Donoghue, Robert P Giugliano, Stephen D Wiviott, et al.
Annals of Medicine|April 5, 2021
Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation - results from the GARFIELD-AF registryMarita Knudsen Pope, Dan Atar, Arne Svilaas, et al.
JACC. Cardiovascular Imaging|January 16, 2022
Cost-Minimization Analysis for Cardiac Revascularization in 12 Health Care Systems Based on the EuroCMR/SPINS RegistriesKarine Moschetti, Raymond Y Kwong, Steffen E Petersen, et al.
The American Journal of Medicine|July 16, 2019
Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AFFreek W A Verheugt, Giuseppe Ambrosio, Dan Atar, et al.
European Journal of Heart Failure|March 3, 2022
Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fractionClara Saldarriaga, Dan Atar, Amanda Stebbins, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 24, 2019
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on StrokePatrick Sulzgruber, Sven Wassmann, Anne Grete Semb, et al.
JACC. Cardiovascular Imaging|September 13, 2014
Prognostic value of microvascular obstruction and infarct size, as measured by CMR in STEMI patientsMatthijs van Kranenburg, Michael Magro, Holger Thiele, et al.
European Heart Journal|September 22, 2019
Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1Patrick Sulzgruber, Sven Wassmann, Anne Grete Semb, et al.
European Heart Journal|October 23, 2013
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trialJohn H Alexander, Renato D Lopes, Laine Thomas, et al.
Pageof 41